,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,875,1,2,,26747751,4685,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
1,880,2,1,,26747751,4685,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
2,880,2,1,,26747751,4685,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
3,881,2,2,,26747751,4685,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
4,884,1,2,,26747751,4685,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
5,885,1,2,,26747751,4685,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
6,887,1,2,,26747751,4685,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
7,889,1,3,,26747751,4685,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
8,892,1,2,,26747751,4685,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
9,893,1,2,,26747751,4685,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
10,893,1,2,,26747751,4685,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
11,894,2,1,,26747751,4685,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
12,900,1,3,,26747751,4685,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
13,902,1,2,,26747751,4685,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
14,910,1,2,,26747751,4685,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 654 locus,Confirmatory,,
15,923,1,2,,26747751,4685,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
16,924,1,2,,26747751,4685,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
17,927,1,3,,26747751,4685,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
18,930,1,2,,26747751,4685,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 705 locus,Confirmatory,,
19,940,1,2,,26613392,4685,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
20,995,1,2,,26747751,4685,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
21,1030,2,1,,26747751,4685,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
22,1189,1,5,,48413573,4685,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary SingleCellCall Results,Other,,
23,1194,1,3,,48413573,4685,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Salmonella Mutagenicity,Other,,
24,1199,1,3,,48413573,4685,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Mouse Bioassay Results,Other,,
25,1205,1,4,,48413573,4685,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary MultiCellCall Results,Other,,
26,1208,1,3,,48413573,4685,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Rat Bioassay Results,Other,,
27,1379,1,2,,26747751,4685,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
28,1422,1,1,,26613392,4685,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
29,1452,1,1,,26747751,4685,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
30,1454,1,1,,26747751,4685,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
31,1457,1,1,,26747751,4685,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
32,1458,1,1,,26747751,4685,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
33,1460,1,3,,26747751,4685,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
34,1463,1,1,,26747751,4685,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
35,1467,1,3,,26747751,4685,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
36,1468,1,1,,26747751,4685,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
37,1469,1,1,,26747751,4685,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
38,1471,2,1,,26747751,4685,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
39,1476,2,1,,26747751,4685,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
40,1478,2,1,,26747751,4685,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
41,1479,1,2,,26747751,4685,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
42,1487,1,1,,26747751,4685,Inconclusive,27436948.0,4000.0,35.4813,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
43,1490,2,1,,26747751,4685,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
44,1519,1,3,,26747751,4685,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
45,1688,1,1,,26747751,4685,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
46,1766,1,1,,26747751,4685,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
47,1766,1,1,,26747751,4685,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
48,1768,1,1,,26747751,4685,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
49,1768,1,1,,26747751,4685,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
50,1865,1,1,,26747751,4685,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
51,1948,1,1,,26747751,4685,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
52,2101,1,1,,26747751,4685,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
53,2107,1,1,,26747751,4685,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
54,2112,1,1,,26747751,4685,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
55,2147,1,1,,26747751,4685,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
56,2451,1,2,,26747751,4685,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
57,2472,1,2,,26747751,4685,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
58,2517,2,1,,144204845,4685,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
59,2528,1,2,,26747751,4685,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
60,2546,1,1,,26747751,4685,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
61,2549,1,1,,26747751,4685,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
62,2551,1,1,,26747751,4685,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
63,2662,2,1,,26747751,4685,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
64,241172,6,7,,103464714,4685,Active,308153612.0,1548.0,17.0,IC50,Inhibitory concentration against human cytochrome P450 2A6,Confirmatory,15658857.0,
65,241174,6,5,,103464714,4685,Active,117196.0,13087.0,1.0,IC50,Inhibitory concentration against mouse cytochrome P450 2A5,Confirmatory,15658857.0,
66,242975,3,5,,103464714,4685,Unspecified,,,,,Ratio of IC50 for human CYP2A6 to that of mouse CYP2A5 was determined,Other,15658857.0,
67,409958,3,9,,103464714,4685,Inactive,124028637.0,281293.0,,,Inhibition of bovine brain MAOA,Other,18834112.0,
68,420670,5,7,,103464714,4685,Active,117196.0,13087.0,1.0,IC50,Inhibition of mouse CYP2A5,Confirmatory,19110342.0,
69,420671,5,7,,103464714,4685,Active,308153612.0,1548.0,16.9824,IC50,Inhibition of human CYP2A6,Confirmatory,19110342.0,
70,433903,3,3,,103464714,4685,Unspecified,,,,,Hepatotoxicity in mouse assessed as carcinogenic potency,Other,19272677.0,
71,485281,1,1,,26747751,4685,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
72,485290,1,1,,26747751,4685,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
73,492961,1,1,,26747751,4685,Inactive,72386991.0,3656265.0,,Potency,qHTS Assay to Find Inhibitors of T. brucei phosphofructokinase: hit validation,Confirmatory,,
74,504327,1,1,,26747751,4685,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
75,504332,1,1,,26747751,4685,Inactive,168985070.0,,,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
76,504749,1,3,,26747751,4685,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
77,504749,1,3,1.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
78,504749,1,3,2.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
79,504749,1,3,3.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
80,504749,1,3,4.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
81,504749,1,3,5.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
82,504749,1,3,6.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
83,504749,1,3,7.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
84,504749,1,3,8.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
85,504749,1,3,9.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
86,504749,1,3,10.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
87,504749,1,3,11.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
88,504749,1,3,12.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
89,504749,1,3,13.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
90,504749,1,3,14.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
91,504749,1,3,15.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
92,504749,1,3,16.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
93,504749,1,3,17.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
94,504749,1,3,18.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
95,504749,1,3,19.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
96,504749,1,3,20.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
97,504749,1,3,21.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
98,504749,1,3,22.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
99,504749,1,3,23.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
100,504749,1,3,24.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
101,504749,1,3,25.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
102,504749,1,3,26.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
103,504749,1,3,27.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
104,504749,1,3,28.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
105,504749,1,3,29.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
106,504749,1,3,30.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
107,504749,1,3,31.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
108,504749,1,3,32.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
109,504749,1,3,33.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
110,504749,1,3,34.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
111,504749,1,3,35.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
112,504749,1,3,36.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
113,504749,1,3,37.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
114,504749,1,3,38.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
115,504749,1,3,39.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
116,504749,1,3,40.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
117,504749,1,3,41.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
118,504749,1,3,42.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
119,504749,1,3,43.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
120,504749,1,3,44.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
121,504749,1,3,45.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
122,504749,1,3,46.0,26747751,4685,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
123,504749,1,3,47.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
124,504749,1,3,48.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
125,504749,1,3,49.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
126,504749,1,3,50.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
127,504749,1,3,51.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
128,504749,1,3,52.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
129,504749,1,3,53.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
130,504749,1,3,54.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
131,504749,1,3,55.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
132,504749,1,3,56.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
133,504749,1,3,57.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
134,504749,1,3,58.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
135,504749,1,3,59.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
136,504749,1,3,60.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
137,504749,1,3,61.0,26747751,4685,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
138,504832,1,1,,26747751,4685,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
139,504834,1,1,,26747751,4685,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
140,504847,1,1,,26747751,4685,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
141,504865,1,1,,26747751,4685,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
142,512732,1,3,,103464714,4685,Active,,,,,Antiapoptotic activity against Caenorhabditis elegans ced-3(n2438) mutant assessed as increase in number of extra cells in anterior pharynx kept in drug exposed air tight plastic storage box at 0.06 g/L in air,Other,16699520.0,
143,512733,1,3,,103464714,4685,Active,,,,,Antiapoptotic activity against Caenorhabditis elegans ced-3(n2438) mutant assessed as increase in number of extra cells in anterior pharynx kept in drug exposed air tight plastic storage box at 0.6 g/L in air,Other,16699520.0,
144,512734,1,3,,103464714,4685,Active,,,,,Antiapoptotic activity against Caenorhabditis elegans ced-3(n2438) mutant assessed as increase in number of extra cells kept in anterior pharynx in gaseous compound exposed air tight plastic storage box at 4 uM,Other,16699520.0,
145,512736,1,3,,103464714,4685,Unspecified,,,,,Antiapoptotic activity against Caenorhabditis elegans ced-3(n2438) mutant assessed as number of extra cells in anterior pharynx compound dissolved in soybean oil,Other,16699520.0,
146,512744,1,3,,103464714,4685,Active,,,,,Antiapoptotic activity against Caenorhabditis elegans ced-3(n2438) G474R mutant assessed as number of extra cells in anterior pharynx L3 and L4 larvae at 250 mM dissolved in soybean oil,Other,16699520.0,
147,513040,1,3,,103464714,4685,Active,,,,,Antiapoptotic activity against Caenorhabditis elegans ced-3(n2447) S446L mutant assessed as number of extra cells in anterior pharynx L3 and L4 larvae at 250 mM dissolved in soybean oil,Other,16699520.0,
148,513041,1,3,,103464714,4685,Active,,,,,Antiapoptotic activity against Caenorhabditis elegans ced-3(n2436) mutant assessed as number of extra cells in anterior pharynx L3 and L4 larvae at 250 mM dissolved in soybean oil,Other,16699520.0,
149,513042,1,3,,103464714,4685,Active,,,,,Antiapoptotic activity against Caenorhabditis elegans ced-4(n2273) mutant assessed as number of extra cells in anterior pharynx L3 and L4 larvae at 250 mM dissolved in soybean oil,Other,16699520.0,
150,513043,1,3,,103464714,4685,Active,,,,,Antiapoptotic activity against Caenorhabditis elegans ced-8(n1891) mutant assessed as number of extra cells in anterior pharynx L3 and L4 larvae at 250 mM dissolved in soybean oil,Other,16699520.0,
151,513044,1,3,,103464714,4685,Active,,,,,Antiapoptotic activity against Caenorhabditis elegans ced-9(n1950) mutant assessed as number of extra cells in anterior pharynx L3 and L4 larvae at 250 mM dissolved in soybean oil,Other,16699520.0,
152,513045,1,3,,103464714,4685,Active,,,,,Antiapoptotic activity against Caenorhabditis elegans ced-3(n2433) mutant assessed as number of extra cells in anterior pharynx L3 and L4 larvae at 250 mM dissolved in soybean oil,Other,16699520.0,
153,513046,3,7,,103464714,4685,Active,19859536.0,178272.0,,,Inhibition of Caenorhabditis elegans CED-3-mediated apoptosis assessed as [35]S methionine labeled CED-9 cleavage product at 100 uM after 2 hrs by fluorescence assay,Other,16699520.0,
154,513047,3,8,,103464714,4685,Active,77416852.0,836.0,,,Inhibition of human caspase-3-mediated apoptosis assessed as appearance of [35]S methionine-labeled PARP cleavage product at 100 uM after 2 hrs by fluorescence assay,Other,16699520.0,
155,513048,3,8,,103464714,4685,Active,77416852.0,836.0,,,Inhibition of human caspase-3-mediated apoptosis assessed as Ac-DEVD-7-amino-4-methylcoumarin cleavage product at 100 uM by fluorescence assay,Other,16699520.0,
156,513049,1,3,,103464714,4685,Active,,,,,Antiapoptotic activity against wild-type Caenorhabditis elegans assessed as reduction in number of cell cropses at comma stage of embryo at 200 uM dissolved in soybean oil,Other,16699520.0,
157,513050,1,3,,103464714,4685,Active,,,,,Antiapoptotic activity against wild-type Caenorhabditis elegans assessed as reduction in number of cell cropses at 1.5 fold stage of embryo at 200 uM dissolved in soybean oil,Other,16699520.0,
158,513051,1,3,,103464714,4685,Active,,,,,Antiapoptotic activity against wild-type Caenorhabditis elegans assessed as reduction in number of cell cropses at 2-fold stage of embryo at 200 uM dissolved in soybean oil,Other,16699520.0,
159,513052,1,3,,103464714,4685,Active,,,,,Antiapoptotic activity against wild-type Caenorhabditis elegans assessed as reduction in number of cell cropses at 4-fold stage of embryo at 200 uM dissolved in soybean oil,Other,16699520.0,
160,513053,1,3,,103464714,4685,Active,,,,,Antiapoptotic activity against wild-type Caenorhabditis elegans assessed as reduction in number of cell cropses at comma stage of embryo at 250 uM dissolved in soybean oil,Other,16699520.0,
161,513054,1,3,,103464714,4685,Active,,,,,Antiapoptotic activity against wild-type Caenorhabditis elegans assessed as reduction in number of cell cropses at 1.5 fold stage of embryo at 250 uM dissolved in soybean oil,Other,16699520.0,
162,513055,1,3,,103464714,4685,Active,,,,,Antiapoptotic activity against wild-type Caenorhabditis elegans assessed as reduction in number of cell cropses at 2-fold stage of embryo at 250 uM dissolved in soybean oil,Other,16699520.0,
163,513056,1,3,,103464714,4685,Active,,,,,Antiapoptotic activity against wild-type Caenorhabditis elegans assessed as reduction in number of cell cropses at 4-fold stage of embryo at 250 uM dissolved in soybean oil,Other,16699520.0,
164,513057,1,3,,103464714,4685,Active,,,,,Antiapoptotic activity against Caenorhabditis elegans engulfment-deffective ced-1(e1735) mutant assessed as reduction in number of cell cropses at comma stage of embryo at 200 uM dissolved in soybean oil,Other,16699520.0,
165,513058,1,3,,103464714,4685,Active,,,,,Antiapoptotic activity against Caenorhabditis elegans engulfment-deffective ced-1(e1735) mutant assessed as reduction in number of cell cropses at 1.5-fold stage of embryo at 200 uM dissolved in soybean oil,Other,16699520.0,
166,513059,1,3,,103464714,4685,Active,,,,,Antiapoptotic activity against Caenorhabditis elegans engulfment-deffective ced-1(e1735) mutant assessed as reduction in number of cell cropses at 2-fold stage of embryo at 200 uM dissolved in soybean oil,Other,16699520.0,
167,513060,1,3,,103464714,4685,Active,,,,,Antiapoptotic activity against Caenorhabditis elegans engulfment-deffective ced-1(e1735) mutant assessed as reduction in number of cell cropses at comma 4-fold of embryo at 200 uM dissolved in soybean oil,Other,16699520.0,
168,513061,1,3,,103464714,4685,Active,,,,,Antiapoptotic activity against Caenorhabditis elegans engulfment-deffective ced-1(e1735) mutant assessed as reduction in number of cell cropses at comma stage of embryo at 250 uM dissolved in soybean oil,Other,16699520.0,
169,513062,1,3,,103464714,4685,Active,,,,,Antiapoptotic activity against Caenorhabditis elegans engulfment-deffective ced-1(e1735) mutant assessed as reduction in number of cell cropses at 1.5-fold stage of embryo at 250 uM dissolved in soybean oil,Other,16699520.0,
170,513063,1,3,,103464714,4685,Active,,,,,Antiapoptotic activity against Caenorhabditis elegans engulfment-deffective ced-1(e1735) mutant assessed as reduction in number of cell cropses at 2-fold stage of embryo at 250 uM dissolved in soybean oil,Other,16699520.0,
171,513064,1,3,,103464714,4685,Active,,,,,Antiapoptotic activity against Caenorhabditis elegans engulfment-deffective ced-1(e1735) mutant assessed as reduction in number of cell cropses at comma 4-fold of embryo at 250 uM dissolved in soybean oil,Other,16699520.0,
172,513065,1,3,,103464714,4685,Active,,,,,Antiapoptotic activity against hermaphroditic wild type Caenorhabditis elegans carrying smls26 transgene assessed as inhibition of male-specific CEM neurons death at 200 mM after 2 hrs,Other,16699520.0,
173,513066,1,3,,103464714,4685,Active,,,,,Antiapoptotic activity against hermaphroditic Caenorhabditis elegans ced-3(n2438) mutant carrying smls26 transgene assessed as inhibition of male-specific CEM neurons death at 200 mM after 2 hrs,Other,16699520.0,
174,513067,1,3,,103464714,4685,Active,,,,,Antiapoptotic activity against hermaphroditic Caenorhabditis elegans ced-3(n2433) mutant carrying smls26 transgene assessed as inhibition of male-specific CEM neurons death at 200 mM after 2 hrs,Other,16699520.0,
175,513068,1,3,,103464714,4685,Active,,,,,Antiapoptotic activity against hermaphroditic wild type Caenorhabditis elegans carrying smls26 transgene assessed as inhibition of male-specific CEM neurons death at 250 mM after 2 hrs,Other,16699520.0,
176,513069,1,3,,103464714,4685,Active,,,,,Antiapoptotic activity against Caenorhabditis elegans ced-3(n2438) mutant carrying smls26 transgene assessed as survival of CEM neurons at 250 mM after 2 hrs,Other,16699520.0,
177,513070,1,3,,103464714,4685,Active,,,,,Antiapoptotic activity against Caenorhabditis elegans ced-3(n2433) mutant carrying smls26 transgene assessed as survival of CEM neurons at 250 mM after 2 hrs,Other,16699520.0,
178,513071,1,3,,103464714,4685,Active,,,,,Antiapoptotic activity against wild type Caenorhabditis elegans carrying nis96 transgene assessed as number of extra VC- cells in postembryonic stage at 200 mM after 2 hrs,Other,16699520.0,
179,513072,1,3,,103464714,4685,Active,,,,,Antiapoptotic activity against Caenorhabditis elegans ced-3(n2438) mutant carrying nis96 transgene assessed as number of extra VC- cells in postembryonic stage at 200 mM after 2 hrs,Other,16699520.0,
180,513073,1,3,,103464714,4685,Active,,,,,Antiapoptotic activity against Caenorhabditis elegans ced-3(n2433) mutant carrying nis96 transgene assessed as number of extra VC- cells in postembryonic stage at 200 mM after 2 hrs,Other,16699520.0,
181,513074,1,3,,103464714,4685,Active,,,,,Antiapoptotic activity against Caenorhabditis elegans carrying nis96 transgene assessed as number of extra VC- cells in postembryonic stage at 250 mM after 2 hrs,Other,16699520.0,
182,513075,1,3,,103464714,4685,Active,,,,,Antiapoptotic activity against Caenorhabditis elegans ced-3(n2438) mutant carrying nis96 transgene assessed as number of extra VC- cells in postembryonic stage at 250 mM after 2 hrs,Other,16699520.0,
183,513076,1,3,,103464714,4685,Active,,,,,Antiapoptotic activity against Caenorhabditis elegans ced-3(n2433) mutant carrying nis96 transgene assessed as number of extra VC- cells in postembryonic stage at 250 mM after 2 hrs,Other,16699520.0,
184,513077,1,3,,103464714,4685,Active,,,,,Suppression of activated CED-3-induced apoptosis expressed in Caenorhabditis elegans ced-1(e1735) mutant assessed as number of cell corpses in 4-fold stage of transgenic line-1 embryo in absence of CED-4,Other,16699520.0,
185,513078,1,3,,103464714,4685,Active,,,,,Suppression of activated CED-3-induced apoptosis expressed in Caenorhabditis elegans ced-4(n1162) mutant assessed as number of cell corpses in 4-fold stage of transgenic line-1 embryo in absence of CED-4,Other,16699520.0,
186,513079,1,3,,103464714,4685,Active,,,,,Suppression of activated CED-3-induced apoptosis expressed in Caenorhabditis elegans ced-1(e1735) mutant assessed as number of cell corpses in 4-fold stage of transgenic line-2 embryo in absence of CED-4,Other,16699520.0,
187,513080,1,3,,103464714,4685,Active,,,,,Suppression of activated CED-3-induced apoptosis expressed in Caenorhabditis elegans ced-4(n1162) mutant assessed as number of cell corpses in 4-fold stage of transgenic line-2 embryo in absence of CED-4,Other,16699520.0,
188,513081,1,3,,103464714,4685,Active,,,,,Suppression of activated CED-3-induced apoptosis expressed in Caenorhabditis elegans ced-1(e1735) mutant assessed as number of cell corpses in 4-fold stage of transgenic line-3 embryo in absence of CED-4,Other,16699520.0,
189,513082,1,3,,103464714,4685,Active,,,,,Suppression of activated CED-3-induced apoptosis expressed in Caenorhabditis elegans ced-4(n1162) mutant assessed as number of cell corpses in 4-fold stage of transgenic line-3 embryo in absence of CED-4,Other,16699520.0,
190,513083,1,3,,103464714,4685,Active,,,,,Suppression of activated CED-3-induced apoptosis expressed in Caenorhabditis elegans ced-1(e1735) mutant assessed as number of cell corpses in 4-fold stage of (smls111) transgenic embryo in absence of CED-4,Other,16699520.0,
191,513084,1,3,,103464714,4685,Active,,,,,Suppression of activated CED-3-induced apoptosis expressed in Caenorhabditis elegans ced-4(n1162) mutant assessed as number of cell corpses in 4-fold stage of (smls111) transgenic embryo in absence of CED-4,Other,16699520.0,
192,513085,1,3,,103464714,4685,Unspecified,,,,,"Octanol-water partition coefficient, log P of the compound",Other,16699520.0,
193,588209,2,3,,103464714,4685,Unspecified,,,,,Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset,Other,20553011.0,
194,588210,2,4,,103464714,4685,Unspecified,,,,,Human drug-induced liver injury (DILI) modelling dataset from Ekins et al,Other,20843939.0,
195,588579,1,1,,26747751,4685,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
196,588834,2,1,,144204845,4685,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
197,602332,1,1,,26747751,4685,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
198,603957,1,3,,103464714,4685,Unspecified,,,,,"Octanol-water partition coefficient, log P of the compound",Other,17629592.0,
199,624030,1,2,,26747751,4685,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
200,624031,1,2,,26747751,4685,Inactive,,,,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
201,624032,1,2,,26747751,4685,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
202,624044,1,2,,26747751,4685,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
203,624170,1,1,,26747751,4685,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
204,624172,1,1,,26747751,4685,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
205,624173,1,3,,26747751,4685,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
206,624263,1,1,,26747751,4685,Inactive,3063388.0,5071.0,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
207,624263,1,1,,26747751,4685,Inactive,37183032.0,,,Potency,A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression,Confirmatory,,
208,624296,1,1,,26747751,4685,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
209,624297,1,1,,26747751,4685,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
210,651631,4,1,,144204845,4685,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
211,651631,4,1,,144207597,4685,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
212,651631,4,1,,144210338,4685,Inactive,269849759.0,7157.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
213,651632,4,1,,144204845,4685,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
214,651632,4,1,,144207597,4685,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
215,651632,4,1,,144210338,4685,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
216,651633,4,1,,144204845,4685,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
217,651633,4,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
218,651633,4,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
219,651634,4,1,,144204845,4685,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
220,651634,4,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
221,651634,4,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
222,652048,1,2,,144204845,4685,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
223,652051,1,1,,144204845,4685,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
224,686978,1,1,,144204845,4685,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
225,686979,1,1,,144204845,4685,Inactive,79154014.0,55775.0,,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
226,720516,2,1,,144204845,4685,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
227,720516,2,1,,144207597,4685,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
228,720516,2,1,,144210338,4685,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
229,720532,1,1,,144204845,4685,Inactive,420597.0,,,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
230,720533,1,1,,144204845,4685,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
231,720552,2,1,,144204845,4685,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
232,720552,2,1,,144207597,4685,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
233,720552,2,1,,144210338,4685,Inactive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
234,720579,2,1,,144204845,4685,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
235,720580,1,1,,144204845,4685,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
236,720634,2,1,,144204845,4685,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
237,720634,2,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
238,720634,2,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
239,720635,2,1,,144204845,4685,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
240,720635,2,1,,144207597,4685,Inconclusive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
241,720635,2,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
242,720637,2,1,,144204845,4685,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
243,720637,2,1,,144207597,4685,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
244,720637,2,1,,144210338,4685,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
245,720674,2,2,,144204845,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
246,720674,2,2,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
247,720674,2,2,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
248,720675,2,2,,144204845,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
249,720675,2,2,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
250,720675,2,2,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
251,720678,2,1,,144204845,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
252,720678,2,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
253,720678,2,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
254,720679,2,1,,144204845,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
255,720679,2,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
256,720679,2,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
257,720680,2,1,,144204845,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
258,720680,2,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
259,720680,2,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
260,720681,2,1,,144204845,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
261,720681,2,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
262,720681,2,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
263,720682,2,1,,144204845,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
264,720682,2,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
265,720682,2,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
266,720683,2,1,,144204845,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
267,720683,2,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
268,720683,2,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
269,720684,2,1,,144204845,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
270,720684,2,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
271,720684,2,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
272,720685,2,1,,144204845,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
273,720685,2,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
274,720685,2,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
275,720686,2,1,,144204845,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
276,720686,2,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
277,720686,2,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
278,720687,2,2,,144204845,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
279,720687,2,2,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
280,720687,2,2,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
281,720691,4,1,,144204845,4685,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
282,720691,4,1,,144207597,4685,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
283,720691,4,1,,144210338,4685,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
284,720692,3,1,,144204845,4685,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
285,720692,3,1,,144207597,4685,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
286,720692,3,1,,144210338,4685,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
287,720693,3,1,,144204845,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
288,720693,3,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
289,720693,3,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
290,720719,2,1,,144204845,4685,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
291,720719,2,1,,144207597,4685,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
292,720719,2,1,,144210338,4685,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
293,720725,2,1,,144204845,4685,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
294,720725,2,1,,144207597,4685,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
295,720725,2,1,,144210338,4685,Inactive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
296,743012,3,1,,144204845,4685,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
297,743012,3,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
298,743012,3,1,,144210338,4685,Inconclusive,,,27.305999999999997,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
299,743014,3,1,,144204845,4685,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
300,743014,3,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
301,743014,3,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
302,743015,3,1,,144204845,4685,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
303,743015,3,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
304,743015,3,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
305,743033,3,1,,144204845,4685,Inconclusive,,,30.1065,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
306,743033,3,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
307,743033,3,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
308,743035,2,1,,144204845,4685,Inconclusive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
309,743035,2,1,,144207597,4685,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
310,743035,2,1,,144210338,4685,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
311,743036,2,1,,144204845,4685,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
312,743036,2,1,,144207597,4685,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
313,743036,2,1,,144210338,4685,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
314,743040,3,1,,144204845,4685,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
315,743040,3,1,,144207597,4685,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
316,743040,3,1,,144210338,4685,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
317,743041,3,1,,144204845,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
318,743041,3,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
319,743041,3,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
320,743042,3,1,,144204845,4685,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
321,743042,3,1,,144207597,4685,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
322,743042,3,1,,144210338,4685,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
323,743053,2,1,,144204845,4685,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
324,743053,2,1,,144207597,4685,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
325,743053,2,1,,144210338,4685,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
326,743054,2,1,,144204845,4685,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
327,743054,2,1,,144207597,4685,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
328,743054,2,1,,144210338,4685,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
329,743063,2,1,,144204845,4685,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
330,743063,2,1,,144207597,4685,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
331,743063,2,1,,144210338,4685,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
332,743064,3,1,,144204845,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
333,743064,3,1,,144207597,4685,Inconclusive,,,68.5199,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
334,743064,3,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
335,743065,3,1,,144204845,4685,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
336,743065,3,1,,144207597,4685,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
337,743065,3,1,,144210338,4685,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
338,743066,3,1,,144204845,4685,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
339,743066,3,1,,144207597,4685,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
340,743066,3,1,,144210338,4685,Inactive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
341,743067,2,1,,144204845,4685,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
342,743067,2,1,,144207597,4685,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
343,743067,2,1,,144210338,4685,Inactive,399498506.0,24831.0,,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
344,743069,2,1,,144204845,4685,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
345,743069,2,1,,144207597,4685,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
346,743069,2,1,,144210338,4685,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
347,743074,2,1,,144204845,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
348,743074,2,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
349,743074,2,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
350,743075,2,1,,144204845,4685,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
351,743075,2,1,,144207597,4685,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
352,743075,2,1,,144210338,4685,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
353,743077,2,1,,144204845,4685,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
354,743077,2,1,,144207597,4685,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
355,743077,2,1,,144210338,4685,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
356,743078,2,1,,144204845,4685,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
357,743078,2,1,,144207597,4685,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
358,743078,2,1,,144210338,4685,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
359,743079,3,1,,144204845,4685,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
360,743079,3,1,,144207597,4685,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
361,743079,3,1,,144210338,4685,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
362,743080,3,1,,144204845,4685,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
363,743080,3,1,,144207597,4685,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
364,743080,3,1,,144210338,4685,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
365,743081,3,1,,144204845,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
366,743081,3,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
367,743081,3,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
368,743083,3,1,,144204845,4685,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
369,743083,3,1,,144207597,4685,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
370,743083,3,1,,144210338,4685,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
371,743084,3,1,,144204845,4685,Inconclusive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
372,743084,3,1,,144207597,4685,Inconclusive,,,61.0684,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
373,743084,3,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
374,743085,3,1,,144204845,4685,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
375,743085,3,1,,144207597,4685,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
376,743085,3,1,,144210338,4685,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
377,743086,3,1,,144204845,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
378,743086,3,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
379,743086,3,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
380,743091,2,1,,144204845,4685,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
381,743091,2,1,,144207597,4685,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
382,743091,2,1,,144210338,4685,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
383,743094,3,1,,144204845,4685,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
384,743094,3,1,,144207597,4685,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
385,743094,3,1,,144210338,4685,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
386,743122,2,1,,144204845,4685,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
387,743122,2,1,,144207597,4685,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
388,743122,2,1,,144210338,4685,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
389,743139,2,1,,144204845,4685,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
390,743139,2,1,,144207597,4685,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
391,743139,2,1,,144210338,4685,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
392,743140,2,1,,144204845,4685,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
393,743140,2,1,,144207597,4685,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
394,743140,2,1,,144210338,4685,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
395,743191,3,1,,144207597,4685,Inactive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
396,743191,3,1,,144210338,4685,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
397,743194,3,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
398,743194,3,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
399,743199,2,1,,144207597,4685,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
400,743199,2,1,,144210338,4685,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
401,743202,4,1,,144207597,4685,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
402,743202,4,1,,144210338,4685,Inactive,20149576.0,4780.0,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
403,743203,3,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
404,743203,3,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
405,743209,3,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
406,743209,3,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
407,743210,4,1,,144207597,4685,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
408,743210,4,1,,144210338,4685,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
409,743211,3,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
410,743211,3,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
411,743212,3,1,,144207597,4685,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
412,743212,3,1,,144210338,4685,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
413,743213,3,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
414,743213,3,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
415,743215,3,1,,144207597,4685,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
416,743215,3,1,,144210338,4685,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
417,743217,3,1,,144207597,4685,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
418,743217,3,1,,144210338,4685,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
419,743218,3,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
420,743218,3,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
421,743219,3,1,,144207597,4685,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
422,743219,3,1,,144210338,4685,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
423,743220,3,1,,144207597,4685,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
424,743220,3,1,,144210338,4685,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
425,743221,3,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
426,743221,3,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
427,743222,3,1,,144207597,4685,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
428,743222,3,1,,144210338,4685,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
429,743223,3,1,,144207597,4685,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
430,743223,3,1,,144210338,4685,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
431,743224,3,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
432,743224,3,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
433,743225,3,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
434,743225,3,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
435,743226,2,1,,144207597,4685,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
436,743226,2,1,,144210338,4685,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
437,743227,2,1,,144207597,4685,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
438,743227,2,1,,144210338,4685,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
439,743228,3,1,,144207597,4685,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
440,743228,3,1,,144210338,4685,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
441,743239,2,1,,144207597,4685,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
442,743239,2,1,,144210338,4685,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
443,743240,2,1,,144207597,4685,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
444,743240,2,1,,144210338,4685,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
445,743241,2,1,,144207597,4685,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
446,743241,2,1,,144210338,4685,Inconclusive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
447,743242,2,1,,144207597,4685,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
448,743242,2,1,,144210338,4685,Inactive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
449,743244,1,1,,144204845,4685,Inactive,,,,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
450,923731,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: R040722,Other,,
451,923732,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: R040722,Other,,
452,923733,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: R040722,Other,,
453,923734,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: R040722,Other,,
454,923735,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: R040722,Other,,
455,923736,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: R040722,Other,,
456,924320,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: R040722,Other,,
457,924321,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: R040722,Other,,
458,924322,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: R040722,Other,,
459,924323,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: R040722,Other,,
460,924324,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: R040722,Other,,
461,924325,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: R040722,Other,,
462,924326,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: R040722,Other,,
463,925747,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: R040722,Other,,
464,925748,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: R040722,Other,,
465,925749,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: R040722,Other,,
466,925750,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: R040722,Other,,
467,925751,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: R040722,Other,,
468,925752,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: R040722,Other,,
469,925753,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: R040722,Other,,
470,925754,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: R040722,Other,,
471,925755,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: R040722,Other,,
472,925756,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: R040722,Other,,
473,925757,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: R040722,Other,,
474,925758,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: R040722,Other,,
475,925759,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: R040722,Other,,
476,926233,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: R070319,Other,,
477,926234,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: R070319,Other,,
478,926235,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: R070319,Other,,
479,926236,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: R070319,Other,,
480,926237,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: R070319,Other,,
481,926238,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: R070319,Other,,
482,926239,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: R070319,Other,,
483,926240,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: R070319,Other,,
484,926241,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: R070319,Other,,
485,926242,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: R070319,Other,,
486,926243,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: R070319,Other,,
487,926244,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: R070319,Other,,
488,926873,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: R070319,Other,,
489,926874,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: R070319,Other,,
490,926875,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: R070319,Other,,
491,926876,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: R070319,Other,,
492,928851,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: R070319,Other,,
493,928852,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: R070319,Other,,
494,928853,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: R070319,Other,,
495,928854,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: R070319,Other,,
496,928855,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: R070319,Other,,
497,928856,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: R070319,Other,,
498,928857,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: R070319,Other,,
499,928858,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: R070319,Other,,
500,928859,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: R070319,Other,,
501,928860,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: R070319,Other,,
502,928861,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: R070319,Other,,
503,928862,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: R070319,Other,,
504,928863,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: R070319,Other,,
505,928864,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: R070319,Other,,
506,928865,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: R070319,Other,,
507,928888,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: R070319,Other,,
508,930873,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: R070319,Other,,
509,930874,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: R070319,Other,,
510,943451,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: R070319,Other,,
511,943452,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: R070319,Other,,
512,943453,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: R070319,Other,,
513,943454,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: R070319,Other,,
514,943455,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: R070319,Other,,
515,943456,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASO (Basophils); Study_ID: R070319,Other,,
516,943457,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MONO (Monocytes); Study_ID: R070319,Other,,
517,943458,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: R070319,Other,,
518,943459,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYM (Lymphocytes); Study_ID: R070319,Other,,
519,944090,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: R070319,Other,,
520,944091,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: R070319,Other,,
521,944092,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: R070319,Other,,
522,944093,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: R070319,Other,,
523,944094,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: R070319,Other,,
524,944095,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: R070319,Other,,
525,944096,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: EOS (Eosinophils); Study_ID: R070319,Other,,
526,944097,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: R070319,Other,,
527,956405,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: R070319,Other,,
528,956406,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: R070319,Other,,
529,957689,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: R040722,Other,,
530,957690,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: R040722,Other,,
531,957691,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: R040722,Other,,
532,957692,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: R040722,Other,,
533,957693,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: R040722,Other,,
534,957694,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: R040722,Other,,
535,957695,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: R040722,Other,,
536,957696,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: R040722,Other,,
537,958282,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: R070319,Other,,
538,958283,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: R070319,Other,,
539,958284,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: R070319,Other,,
540,958285,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: R070319,Other,,
541,958286,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: R070319,Other,,
542,958287,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: R070319,Other,,
543,958288,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: R070319,Other,,
544,958289,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: R070319,Other,,
545,958290,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: R070319,Other,,
546,958291,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: R070319,Other,,
547,958292,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: R070319,Other,,
548,958293,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: R070319,Other,,
549,958294,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: R070319,Other,,
550,958295,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: R070319,Other,,
551,958296,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: R070319,Other,,
552,958297,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: R070319,Other,,
553,959603,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: R040722,Other,,
554,959604,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: R040722,Other,,
555,959605,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: R040722,Other,,
556,959606,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: R040722,Other,,
557,959607,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: R040722,Other,,
558,959608,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: R040722,Other,,
559,959609,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: R040722,Other,,
560,959610,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: R040722,Other,,
561,959611,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: R040722,Other,,
562,959612,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: R040722,Other,,
563,962206,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: R040722,Other,,
564,963195,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: R040722,Other,,
565,963196,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: R040722,Other,,
566,963197,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: R040722,Other,,
567,963198,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: R040722,Other,,
568,963199,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: R040722,Other,,
569,963200,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: R040722,Other,,
570,963201,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: R040722,Other,,
571,963202,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: R040722,Other,,
572,963203,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: R040722,Other,,
573,963204,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: R040722,Other,,
574,963205,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: R040722,Other,,
575,963206,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: R040722,Other,,
576,963207,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: R040722,Other,,
577,963208,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: R040722,Other,,
578,963209,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: R040722,Other,,
579,964651,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: R040722,Other,,
580,965029,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: R040722,Other,,
581,965030,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: R040722,Other,,
582,965031,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: R040722,Other,,
583,969926,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: R070319,Other,,
584,969927,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: R070319,Other,,
585,969928,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: R070319,Other,,
586,969929,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: R070319,Other,,
587,969930,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: R070319,Other,,
588,969931,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: R070319,Other,,
589,969932,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: R070319,Other,,
590,969933,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: R070319,Other,,
591,969934,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: R070319,Other,,
592,969935,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: R070319,Other,,
593,969936,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: R070319,Other,,
594,969937,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: R070319,Other,,
595,969938,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: R070319,Other,,
596,969939,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: R070319,Other,,
597,969940,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: R070319,Other,,
598,969941,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: R070319,Other,,
599,969942,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: R070319,Other,,
600,969943,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: R070319,Other,,
601,969944,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: R070319,Other,,
602,972557,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: R070319,Other,,
603,972558,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: R070319,Other,,
604,972559,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: R070319,Other,,
605,972560,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: R070319,Other,,
606,972561,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: R070319,Other,,
607,972562,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: R070319,Other,,
608,972563,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: R070319,Other,,
609,972564,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: R070319,Other,,
610,972565,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: R070319,Other,,
611,972566,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: R070319,Other,,
612,972567,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: R070319,Other,,
613,972568,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: R070319,Other,,
614,972569,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: R070319,Other,,
615,972570,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: R070319,Other,,
616,972571,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: R070319,Other,,
617,972572,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: R070319,Other,,
618,972573,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: R070319,Other,,
619,972574,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: R070319,Other,,
620,977599,1,1,,103464714,4685,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
621,977602,1,2,,103464714,4685,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
622,982427,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mixed Cell; Study_ID: R040722",Other,,
623,982428,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040722",Other,,
624,982429,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Autolysis; Study_ID: R040722,Other,,
625,982430,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Fibrosis; Study_ID: R040722",Other,,
626,982431,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Myocyte, Degeneration; Study_ID: R040722",Other,,
627,982432,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040722",Other,,
628,982433,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Polymorphonuclear Cell; Study_ID: R040722",Other,,
629,982434,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Mononuclear Cell; Study_ID: R040722",Other,,
630,982435,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Mineralization; Study_ID: R040722",Other,,
631,982436,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Tubule, Regeneration; Study_ID: R040722",Other,,
632,982437,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Fibrosis; Study_ID: R040722",Other,,
633,982438,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Tubule, Dilatation; Study_ID: R040722",Other,,
634,982439,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Nephropathy; Study_ID: R040722,Other,,
635,982440,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mixed Cell; Study_ID: R040722",Other,,
636,982441,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040722",Other,,
637,982442,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Degeneration; Study_ID: R040722",Other,,
638,982443,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Lipid Accumulation; Study_ID: R040722",Other,,
639,982444,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Inflammation, Chronic; Study_ID: R040722",Other,,
640,982911,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Mineralization; Study_ID: R040722",Other,,
641,982912,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Necrosis; Study_ID: R040722",Other,,
642,982913,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Degeneration; Study_ID: R040722",Other,,
643,982914,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Edema; Study_ID: R040722",Other,,
644,982915,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: R040722,Other,,
645,982916,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Fibrosis; Study_ID: R040722",Other,,
646,982917,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mixed Cell; Study_ID: R040722",Other,,
647,982918,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040722",Other,,
648,982919,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Vacuolation; Study_ID: R040722",Other,,
649,982920,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Fibrosis; Study_ID: R040722",Other,,
650,982921,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Mineralization; Study_ID: R040722",Other,,
651,982922,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Cyst(S); Study_ID: R040722",Other,,
652,982923,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Hyperplasia; Study_ID: R040722",Other,,
653,982924,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040722",Other,,
654,982925,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Necrosis, Fibrinoid; Study_ID: R040722",Other,,
655,982926,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Fibrosis; Study_ID: R040722",Other,,
656,982927,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: R040722,Other,,
657,982928,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Dilatation; Study_ID: R040722",Other,,
658,982929,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040722",Other,,
659,982930,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Myocyte, Degeneration; Study_ID: R040722",Other,,
660,982931,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Inflammation, Subacute; Study_ID: R040722",Other,,
661,982932,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Urothelial Hyperplasia; Study_ID: R040722",Other,,
662,982933,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040722",Other,,
663,982934,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040722",Other,,
664,982935,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Deposit; Study_ID: R040722",Other,,
665,982936,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Dilatation; Study_ID: R040722",Other,,
666,982937,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Hyaline Droplets; Study_ID: R040722",Other,,
667,982938,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Necrosis; Study_ID: R040722",Other,,
668,982939,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Endocardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040722",Other,,
669,982940,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Tunica Media, Hypertrophy; Study_ID: R040722",Other,,
670,982941,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Cyst(S); Study_ID: R040722",Other,,
671,982942,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Myocyte, Degeneration; Study_ID: R040722",Other,,
672,982943,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: R040722",Other,,
673,982944,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Cyst(S); Study_ID: R040722",Other,,
674,982945,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Regeneration; Study_ID: R040722",Other,,
675,982946,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mixed Cell; Study_ID: R040722",Other,,
676,982947,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Fibrosis; Study_ID: R040722",Other,,
677,982948,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Myocyte, Degeneration; Study_ID: R040722",Other,,
678,982949,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: R040722",Other,,
679,982950,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 6 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Cast, Proteinaceous; Study_ID: R040722",Other,,
680,994783,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Myocyte, Degeneration; Study_ID: R070319",Other,,
681,994784,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mixed Cell; Study_ID: R070319",Other,,
682,994785,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: R070319",Other,,
683,994786,1,4,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Gastrocnemius, Myocyte, Degeneration; Study_ID: R070319",Other,,
684,994787,1,4,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Gastrocnemius, Myocyte, Inflammation; Study_ID: R070319",Other,,
685,994788,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Mineralization; Study_ID: R070319",Other,,
686,994789,1,4,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Inflammation; Study_ID: R070319",Other,,
687,994790,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Fibrosis; Study_ID: R070319",Other,,
688,994791,1,4,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Soleus, Myocyte, Regeneration; Study_ID: R070319",Other,,
689,994792,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mixed Cell; Study_ID: R070319",Other,,
690,994793,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mixed Cell; Study_ID: R070319",Other,,
691,994794,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Degeneration; Study_ID: R070319",Other,,
692,994795,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Degeneration; Study_ID: R070319",Other,,
693,994796,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R070319",Other,,
694,994797,1,4,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Gastrocnemius, Myocyte, Regeneration; Study_ID: R070319",Other,,
695,994798,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Necrosis, Fibrinoid; Study_ID: R070319",Other,,
696,994799,1,4,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Degeneration; Study_ID: R070319",Other,,
697,994800,1,4,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Regeneration; Study_ID: R070319",Other,,
698,994801,1,4,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Soleus, Myocyte, Degeneration; Study_ID: R070319",Other,,
699,994802,1,4,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Soleus, Myocyte, Inflammation; Study_ID: R070319",Other,,
700,994803,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: R070319",Other,,
701,1006187,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Degeneration; Study_ID: R070319",Other,,
702,1006188,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R070319",Other,,
703,1006189,1,4,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Gastrocnemius, Myocyte, Regeneration; Study_ID: R070319",Other,,
704,1006190,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Necrosis, Fibrinoid; Study_ID: R070319",Other,,
705,1006191,1,4,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Degeneration; Study_ID: R070319",Other,,
706,1006192,1,4,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Regeneration; Study_ID: R070319",Other,,
707,1006193,1,4,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Soleus, Myocyte, Degeneration; Study_ID: R070319",Other,,
708,1006194,1,4,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Soleus, Myocyte, Inflammation; Study_ID: R070319",Other,,
709,1006195,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: R070319",Other,,
710,1006196,1,4,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Gastrocnemius, Myocyte, Degeneration; Study_ID: R070319",Other,,
711,1014199,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Myocyte, Degeneration; Study_ID: R070319",Other,,
712,1014200,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mixed Cell; Study_ID: R070319",Other,,
713,1014201,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: R070319",Other,,
714,1014202,1,4,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Gastrocnemius, Myocyte, Inflammation; Study_ID: R070319",Other,,
715,1014203,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Mineralization; Study_ID: R070319",Other,,
716,1014204,1,4,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Inflammation; Study_ID: R070319",Other,,
717,1014205,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Fibrosis; Study_ID: R070319",Other,,
718,1014206,1,4,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Soleus, Myocyte, Regeneration; Study_ID: R070319",Other,,
719,1014207,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mixed Cell; Study_ID: R070319",Other,,
720,1014208,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mixed Cell; Study_ID: R070319",Other,,
721,1014209,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Degeneration; Study_ID: R070319",Other,,
722,1014238,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Myocyte, Degeneration; Study_ID: R070319",Other,,
723,1014239,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mixed Cell; Study_ID: R070319",Other,,
724,1014240,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: R070319",Other,,
725,1014241,1,4,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Gastrocnemius, Myocyte, Degeneration; Study_ID: R070319",Other,,
726,1014242,1,4,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Gastrocnemius, Myocyte, Inflammation; Study_ID: R070319",Other,,
727,1014243,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Mineralization; Study_ID: R070319",Other,,
728,1014244,1,4,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Inflammation; Study_ID: R070319",Other,,
729,1014245,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Fibrosis; Study_ID: R070319",Other,,
730,1014246,1,4,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Soleus, Myocyte, Regeneration; Study_ID: R070319",Other,,
731,1014247,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mixed Cell; Study_ID: R070319",Other,,
732,1014248,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mixed Cell; Study_ID: R070319",Other,,
733,1014249,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Degeneration; Study_ID: R070319",Other,,
734,1014250,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Degeneration; Study_ID: R070319",Other,,
735,1014251,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R070319",Other,,
736,1014252,1,4,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Gastrocnemius, Myocyte, Regeneration; Study_ID: R070319",Other,,
737,1014253,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Necrosis, Fibrinoid; Study_ID: R070319",Other,,
738,1014254,1,4,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Degeneration; Study_ID: R070319",Other,,
739,1014255,1,4,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Biceps Femoris, Myocyte, Regeneration; Study_ID: R070319",Other,,
740,1014256,1,4,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Soleus, Myocyte, Degeneration; Study_ID: R070319",Other,,
741,1014257,1,4,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Thigh Muscle; Assay: Right Soleus, Myocyte, Inflammation; Study_ID: R070319",Other,,
742,1014258,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Single; Time: 1 day; Dose: High; Vehicle: 100 % corn oil; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: R070319",Other,,
743,1027473,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mixed Cell; Study_ID: R040722",Other,,
744,1027474,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040722",Other,,
745,1027475,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Autolysis; Study_ID: R040722,Other,,
746,1027476,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Fibrosis; Study_ID: R040722",Other,,
747,1027477,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Myocyte, Degeneration; Study_ID: R040722",Other,,
748,1027478,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040722",Other,,
749,1027479,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Polymorphonuclear Cell; Study_ID: R040722",Other,,
750,1027480,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Mononuclear Cell; Study_ID: R040722",Other,,
751,1027481,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Mineralization; Study_ID: R040722",Other,,
752,1027482,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Tubule, Regeneration; Study_ID: R040722",Other,,
753,1027483,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Fibrosis; Study_ID: R040722",Other,,
754,1027484,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Tubule, Dilatation; Study_ID: R040722",Other,,
755,1027485,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Nephropathy; Study_ID: R040722,Other,,
756,1027486,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mixed Cell; Study_ID: R040722",Other,,
757,1027487,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040722",Other,,
758,1027488,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Degeneration; Study_ID: R040722",Other,,
759,1027489,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Lipid Accumulation; Study_ID: R040722",Other,,
760,1027490,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Inflammation, Chronic; Study_ID: R040722",Other,,
761,1027491,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Mineralization; Study_ID: R040722",Other,,
762,1027492,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Necrosis; Study_ID: R040722",Other,,
763,1027493,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Degeneration; Study_ID: R040722",Other,,
764,1027494,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Edema; Study_ID: R040722",Other,,
765,1027495,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: R040722,Other,,
766,1027496,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Fibrosis; Study_ID: R040722",Other,,
767,1029370,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mixed Cell; Study_ID: R040722",Other,,
768,1029371,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040722",Other,,
769,1029372,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Vacuolation; Study_ID: R040722",Other,,
770,1029373,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Fibrosis; Study_ID: R040722",Other,,
771,1029374,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Mineralization; Study_ID: R040722",Other,,
772,1029956,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Cyst(S); Study_ID: R040722",Other,,
773,1029957,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Hyperplasia; Study_ID: R040722",Other,,
774,1029958,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040722",Other,,
775,1029959,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Necrosis, Fibrinoid; Study_ID: R040722",Other,,
776,1029960,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Fibrosis; Study_ID: R040722",Other,,
777,1029961,1,3,,103464714,4685,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: R040722,Other,,
778,1029962,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Dilatation; Study_ID: R040722",Other,,
779,1029963,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040722",Other,,
780,1029964,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Myocyte, Degeneration; Study_ID: R040722",Other,,
781,1029965,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Inflammation, Subacute; Study_ID: R040722",Other,,
782,1029966,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Urothelial Hyperplasia; Study_ID: R040722",Other,,
783,1029967,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040722",Other,,
784,1029968,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040722",Other,,
785,1029969,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Deposit; Study_ID: R040722",Other,,
786,1029970,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Dilatation; Study_ID: R040722",Other,,
787,1029971,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Hyaline Droplets; Study_ID: R040722",Other,,
788,1029972,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Necrosis; Study_ID: R040722",Other,,
789,1029973,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Endocardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040722",Other,,
790,1029974,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Tunica Media, Hypertrophy; Study_ID: R040722",Other,,
791,1029975,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Cyst(S); Study_ID: R040722",Other,,
792,1029976,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Myocyte, Degeneration; Study_ID: R040722",Other,,
793,1029977,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: R040722",Other,,
794,1029978,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Cyst(S); Study_ID: R040722",Other,,
795,1029979,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Regeneration; Study_ID: R040722",Other,,
796,1029980,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mixed Cell; Study_ID: R040722",Other,,
797,1029981,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Fibrosis; Study_ID: R040722",Other,,
798,1029982,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Myocyte, Degeneration; Study_ID: R040722",Other,,
799,1029983,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: R040722",Other,,
800,1029984,1,3,,103464714,4685,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Cast, Proteinaceous; Study_ID: R040722",Other,,
801,1159509,1,1,,144207597,4685,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
802,1159509,1,1,,144210338,4685,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
803,1159515,1,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
804,1159515,1,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
805,1159516,1,1,,144207597,4685,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
806,1159516,1,1,,144210338,4685,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
807,1159517,1,1,,144207597,4685,Inconclusive,,,1.2295,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
808,1159517,1,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
809,1159518,1,1,,144207597,4685,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
810,1159518,1,1,,144210338,4685,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
811,1159519,1,1,,144207597,4685,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
812,1159519,1,1,,144210338,4685,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
813,1159520,1,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
814,1159520,1,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
815,1159521,1,1,,144207597,4685,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
816,1159521,1,1,,144210338,4685,Inactive,15928672.0,19885.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
817,1159523,1,1,,144207597,4685,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
818,1159523,1,1,,144210338,4685,Inactive,15928672.0,19885.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
819,1159524,1,1,,144204845,4685,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
820,1159525,1,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
821,1159525,1,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
822,1159526,1,1,,144207597,4685,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
823,1159526,1,1,,144210338,4685,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
824,1159527,1,1,,144207597,4685,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
825,1159527,1,1,,144210338,4685,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
826,1159528,1,1,,144207597,4685,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
827,1159528,1,1,,144210338,4685,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
828,1159529,1,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
829,1159529,1,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
830,1159531,1,1,,144207597,4685,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
831,1159531,1,1,,144210338,4685,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
832,1159550,3,1,,252402034,4685,Inactive,12653201.0,5226.0,,,Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening,Screening,26479318.0,
833,1159551,1,1,,144207597,4685,Inconclusive,,,27.2783,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
834,1159551,1,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
835,1159552,1,1,,144207597,4685,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
836,1159552,1,1,,144210338,4685,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
837,1159553,2,1,,144207597,4685,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
838,1159553,2,1,,144210338,4685,Inactive,325495463.0,5914.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
839,1159555,1,1,,144207597,4685,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
840,1159555,1,1,,144210338,4685,Inactive,325495463.0,5914.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
841,1159580,2,1,,268736386,4685,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
842,1159607,2,1,,312996162,4685,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
843,1224834,3,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
844,1224834,3,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
845,1224835,1,1,,144207597,4685,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
846,1224835,1,1,,144210338,4685,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
847,1224836,1,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
848,1224836,1,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
849,1224837,1,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
850,1224837,1,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
851,1224838,1,1,,144207597,4685,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
852,1224838,1,1,,144210338,4685,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
853,1224839,1,1,,144207597,4685,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
854,1224839,1,1,,144210338,4685,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
855,1224840,3,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
856,1224840,3,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
857,1224841,3,1,,144207597,4685,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
858,1224841,3,1,,144210338,4685,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
859,1224842,3,1,,144207597,4685,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
860,1224842,3,1,,144210338,4685,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
861,1224843,1,1,,144207597,4685,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
862,1224843,1,1,,144210338,4685,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
863,1224844,1,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
864,1224844,1,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
865,1224845,1,1,,144207597,4685,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
866,1224845,1,1,,144210338,4685,Inactive,344243002.0,100757539.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
867,1224846,1,1,,144207597,4685,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
868,1224846,1,1,,144210338,4685,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
869,1224847,1,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
870,1224847,1,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
871,1224848,3,1,,144207597,4685,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
872,1224848,3,1,,144210338,4685,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
873,1224849,3,1,,144207597,4685,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
874,1224849,3,1,,144210338,4685,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
875,1224867,1,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
876,1224867,1,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
877,1224868,1,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
878,1224868,1,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
879,1224869,1,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
880,1224869,1,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
881,1224870,1,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
882,1224870,1,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
883,1224871,1,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
884,1224871,1,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
885,1224872,1,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
886,1224872,1,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
887,1224873,1,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
888,1224873,1,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
889,1224874,1,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
890,1224874,1,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
891,1224875,1,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
892,1224875,1,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
893,1224876,1,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
894,1224876,1,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
895,1224877,1,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
896,1224877,1,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
897,1224878,1,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
898,1224878,1,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
899,1224879,1,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
900,1224879,1,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
901,1224880,1,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
902,1224880,1,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
903,1224881,1,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
904,1224881,1,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
905,1224882,1,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
906,1224882,1,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
907,1224883,1,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
908,1224883,1,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
909,1224884,1,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
910,1224884,1,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
911,1224885,1,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
912,1224885,1,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
913,1224886,1,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
914,1224886,1,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
915,1224887,1,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
916,1224887,1,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
917,1224888,1,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
918,1224888,1,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
919,1224889,1,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
920,1224889,1,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
921,1224890,1,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
922,1224890,1,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
923,1224892,1,1,,144207597,4685,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
924,1224892,1,1,,144210338,4685,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
925,1224893,1,1,,144207597,4685,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
926,1224893,1,1,,144210338,4685,Inactive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
927,1224894,1,1,,144207597,4685,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
928,1224894,1,1,,144210338,4685,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
929,1224895,1,1,,144207597,4685,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
930,1224895,1,1,,144210338,4685,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
931,1224896,1,1,,144207597,4685,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
932,1224896,1,1,,144210338,4685,Inactive,344243002.0,100757539.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
933,1259241,1,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
934,1259241,1,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
935,1259242,1,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
936,1259242,1,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
937,1259243,1,1,,144207597,4685,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
938,1259243,1,1,,144210338,4685,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
939,1259244,1,1,,144207597,4685,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
940,1259244,1,1,,144210338,4685,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
941,1259247,1,1,,144207597,4685,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
942,1259247,1,1,,144210338,4685,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
943,1259248,1,1,,144207597,4685,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
944,1259248,1,1,,144210338,4685,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
945,1259344,1,1,,144204845,4685,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
946,1259355,1,1,,144204845,4685,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
947,1259356,1,1,,144204845,4685,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
948,1259364,1,1,,144207597,4685,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
949,1259364,1,1,,144210338,4685,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
950,1259365,1,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
951,1259365,1,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
952,1259366,1,1,,144207597,4685,Inconclusive,,,0.9679,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
953,1259366,1,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
954,1259367,1,1,,144207597,4685,Inconclusive,,,0.6852,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
955,1259367,1,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
956,1259368,1,1,,144207597,4685,Inactive,109731339.0,2737.0,0.5443,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
957,1259368,1,1,,144210338,4685,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
958,1259369,1,1,,144207597,4685,Active,109731339.0,2737.0,0.3853,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
959,1259369,1,1,,144210338,4685,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
960,1259377,1,1,,144207597,4685,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
961,1259377,1,1,,144210338,4685,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
962,1259378,1,1,,144207597,4685,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
963,1259378,1,1,,144210338,4685,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
964,1259379,1,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
965,1259379,1,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
966,1259380,1,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
967,1259380,1,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
968,1259381,1,1,,144207597,4685,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
969,1259381,1,1,,144210338,4685,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
970,1259382,1,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
971,1259382,1,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
972,1259383,1,1,,144207597,4685,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
973,1259383,1,1,,144210338,4685,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
974,1259384,1,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
975,1259384,1,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
976,1259385,1,1,,144207597,4685,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
977,1259385,1,1,,144210338,4685,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
978,1259386,1,1,,144207597,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
979,1259386,1,1,,144210338,4685,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
980,1259387,1,1,,144207597,4685,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
981,1259387,1,1,,144210338,4685,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
982,1259388,1,1,,144207597,4685,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
983,1259388,1,1,,144210338,4685,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
984,1259389,1,1,,124637245,4685,Inactive,,,,,HIV1_TAR : FRET assay measuring displacement of FAM and TAMRA-labeled Tat peptide from HIV-1 TAR RNA.,Screening,,
985,1259390,1,1,,144207597,4685,Inconclusive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
986,1259390,1,1,,144210338,4685,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
987,1259391,1,1,,144207597,4685,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
988,1259391,1,1,,144210338,4685,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
989,1259392,1,1,,144207597,4685,Inconclusive,109731339.0,2737.0,0.385316,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
990,1259392,1,1,,144210338,4685,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
991,1259393,1,1,,144207597,4685,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
992,1259393,1,1,,144210338,4685,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
993,1259394,1,1,,144207597,4685,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
994,1259394,1,1,,144210338,4685,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
995,1259395,1,1,,144207597,4685,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
996,1259395,1,1,,144210338,4685,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
997,1259396,1,1,,144207597,4685,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
998,1259396,1,1,,144210338,4685,Inconclusive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
999,1259401,1,1,,144207597,4685,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
1000,1259401,1,1,,144210338,4685,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
1001,1259402,1,1,,144207597,4685,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
1002,1259402,1,1,,144210338,4685,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
1003,1259403,1,1,,144207597,4685,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
1004,1259403,1,1,,144210338,4685,Inactive,325495545.0,2101.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
1005,1259404,1,1,,144207597,4685,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
1006,1259404,1,1,,144210338,4685,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
1007,1259407,1,1,,363898257,4685,Inactive,,,,,CCRIS mutagenicity studies,Other,,
1008,1259408,1,1,,363895266,4685,Active,,,,,GENE-TOX mutagenicity studies,Other,,
1009,1259411,1,1,,363898257,4685,Inactive,,,,,CCRIS carcinogenicity studies,Other,,
1010,1259423,1,2,,354997084,4685,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
